Finasteride Prescribing Information at a Glance
Finasteride prescribing information outlines a prescription-only 5-alpha-reductase inhibitor indicated for the treatment of male pattern baldness (androgenetic alopecia) and symptomatic benign prostatic hyperplasia (BPH). The drug reduces serum and scalp dihydrotestosterone (DHT) levels by approximately 70%, which underlies both its therapeutic benefits and its risk profile. Prescribers should consult the full FDA-approved labeling before initiating therapy, as the complete prescribing information includes detailed pharmacology, drug interaction data, and specific patient selection criteria.
More from this site
Keep reading the latest coverage
Understanding finasteride prescribing information requires attention to the distinction between the 1 mg tablet (for alopecia) and the 5 mg tablet (for BPH). The two formulations are not interchangeable, and dosing errors can lead to unnecessary exposure or subtherapeutic treatment. This overview distills the core elements of finasteride prescribing information that clinicians and informed patients should know.
Approved Indications and Clinical Use
Finasteride prescribing information identifies two primary indications. For male pattern baldness, the 1 mg daily dose is approved to treat vertex and anterior mid-scalp hair loss in men. For BPH, the 5 mg daily dose is approved to improve symptom relief and reduce the risk of acute urinary retention and the need for surgical intervention in men with an enlarged prostate.
Finasteride is not approved for use in women, and finasteride prescribing information explicitly states that the drug is contraindicated in pregnancy. Pregnant women or those who may become pregnant should not handle crushed or broken tablets, as absorption through the skin can cause abnormalities in a male fetus. The prescribing information also notes that finasteride has not been studied in children and should not be used for pediatric conditions.
Dosage and Administration Guidelines
The standard dosing regimen is a key part of finasteride prescribing information. For alopecia, one 1 mg tablet is taken orally once daily. For BPH, one 5 mg tablet is taken orally once daily. Finasteride can be taken with or without food, and the prescribing information notes that the drug's efficacy depends on continuous use; hair regrowth or prostate symptom improvement may take three to six months to become apparent, and treatment should be reassessed if no benefit is observed after 12 months.
Prescribers should counsel patients that missed doses can reduce effectiveness, and that stopping finasteride leads to gradual loss of any gains within 6 to 12 months. The prescribing information does not recommend routine laboratory monitoring for alopecia patients, but for BPH patients, baseline and periodic prostate-specific antigen (PSA) testing remains standard of care.
Contraindications and Precautions
Finasteride prescribing information lists pregnancy and known hypersensitivity to finasteride or any tablet component as the primary contraindications. Women of childbearing potential should not take finasteride, and the drug is classified as Pregnancy Category X in the United States, indicating evidence of fetal risk that outweighs any potential benefit.
Additional precautions in finasteride prescribing information include monitoring for rare but serious adverse events. These include male breast cancer (reported in post-marketing experience), depression, and priapism. The prescribing information notes that while a causal relationship has not been established, clinicians should be aware of these reports when evaluating patients on finasteride.
Adverse Reactions and Drug Interactions
The adverse reaction profile is a central section of finasteride prescribing information. In alopecia trials, the most common adverse reactions occurring at a rate higher than placebo include decreased libido, erectile dysfunction, and ejaculation disorder. These sexual side effects are reported in a small percentage of users, and the prescribing information notes that they may persist after discontinuation in rare cases, a phenomenon sometimes referred to as post-finasteride syndrome.
For BPH, additional reported reactions include gynecomastia and breast tenderness. The prescribing information notes that finasteride alters PSA levels, reducing them by approximately 50%, and clinicians should account for this when interpreting PSA results for prostate cancer screening.
| Attribute | Detail | Context |
|---|---|---|
| Drug Class | 5-alpha-reductase inhibitor | Reduces DHT by ~70% |
| Alopecia Dose | 1 mg orally once daily | Not interchangeable with 5 mg |
| BPH Dose | 5 mg orally once daily | For symptomatic BPH only |
| Onset of Effect | 3 to 6 months | Reassess at 12 months |
| Pregnancy Risk | Category X | Do not handle crushed tablets |
| Key Sexual Side Effects | Decreased libido, ED, ejaculation disorder | Low incidence; may persist after stopping |
| PSA Effect | Reduces PSA by ~50% | Adjust screening interpretation |
Patient Counseling Points from the Prescribing Information
Finasteride prescribing information includes specific counseling points that prescribers should discuss with patients. These include the realistic expectation that hair regrowth varies and that hair loss resumes if treatment stops. Patients should be advised to report any new symptoms of depression, breast lumps or tenderness, or changes in sexual function promptly. The prescribing information also emphasizes that finasteride does not protect against prostate cancer and that PSA monitoring should continue as recommended for the patient's age and risk profile.
For patients considering long-term therapy, finasteride prescribing information supports the safety of continuous use for up to five years in alopecia trials and longer in BPH studies, though the prescriber should periodically reevaluate the benefit-risk balance, particularly in older patients with evolving cardiovascular or metabolic health.